SRINAGAR: A total of 29 pharmaceutical units have been granted registration under the New Central Sector Scheme (NCSS) 2021 for Industrial Development of the Union Territory of Jammu and Kashmir, of which 24 have commenced operations, according to information provided by the Department for Promotion of Industry and Internal Trade.
An amount of Rs 31.76 crore has been disbursed as incentives under the NCSS during the financial year 2025–26, reflecting ongoing efforts to promote industrial growth in the region.
Under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients, one project has been approved in Jammu and Kashmir. The project has seen an investment of Rs 162.01 crore till December 2025, though no incentive has been released so far.
Separately, under the PLI Scheme for Pharmaceuticals, manufacturing has commenced in one unit in the Union Territory, with a total investment of Rs 14.15 crore reported till December 2025.
The Scheme for Promotion of Medical Devices Parks, aimed at providing common infrastructure facilities to medical device manufacturers, is currently being implemented in Greater Noida in Uttar Pradesh, Ujjain in Madhya Pradesh and Kanchipuram in Tamil Nadu. These parks are at an advanced stage of development, with a combined project cost of Rs 871.11 crore and a central grant-in-aid of Rs 100 crore for each park. No such park has been established in Jammu and Kashmir so far.
Similarly, under the Scheme for Promotion of Bulk Drug Parks, approved in March 2020 to facilitate the establishment of three parks across the country, projects have been sanctioned in Andhra Pradesh, Gujarat and Himachal Pradesh during the financial year 2022–23. The scheme provides financial assistance of up to Rs 1,000 crore per park, or 70 per cent of the project cost, with a higher ceiling of 90 per cent for North-Eastern and Himalayan states. Jammu and Kashmir currently does not have a Bulk Drug Park under this scheme.
The measures, including PLI schemes, infrastructure-focused park initiatives and fiscal incentives under NCSS, are aimed at strengthening domestic manufacturing of pharmaceutical raw materials and improving industrial competitiveness through enhanced infrastructure and economies of scale.
The information was provided by Minister of State for Chemicals and Fertilizers Anupriya Patel in a written reply in the Rajya Sabha.
